• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Riociguat(625115-55-1)
Methyl [4,6-diaMino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidin-5-yl]carbaMate
2-[1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidine-4,5,6-triaMine(428854-24-4)
4,6-PyriMidinediaMine, 2-[1-[(2-fluorophenyl)Methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(phenylazo)-
1H-Pyrazolo[3,4-b]pyridine-3-carboximidamide, 1-[(2-fluorophenyl)methyl]-, hydrochloride (1:1)
1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboximidamide(256376-68-8)

NATCO launches Brivaracetam tablets in India

expresspharmaMarch 01, 2021

Tag: NATCO , BRECITA , Brivaracetam , India , Epilepsy

Natco Pharma announced the launch of Brivaracetam tablets under brand BRECITA in India.

Brivaracetam is indicated for the treatment of epilepsy. Brivaracetam is developed by UCB Pharma and currently marketed in India by Dr Reddy’s under the brand name Briviact.

NATCO’s BRECITA tablets will be available in two strengths of 50mg and 100mg at MRP prices of Rs 25/- and Rs 35/- per tablet respectively.

Epilepsy patients in India is estimated to be between 5-10 million, as per GEMIND guidelines.

Previous:Bharat Biotech signs supply deal with Brazil for 20 million doses of COVAXIN

Next:Amneal gets USFDA approval for Norelgestromin and Ethinyl Estradiol Transdermal System

Related News

Macrogen Consortium win tender for National Bio Big Data Project

PRNewswireDecember 23, 2024

Macrogen and Illumina Inc. (NASDAQ: ILMN) announced today that they are honoured to support the National Bio Big Data project by sequencing and analysing 145,952 Korean genomes.

SCG Cell Therapy partners A*STAR to accelerate RNA-based therapeutic development in Singapore

PRNewswireDecember 23, 2024

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

NATCO launches Brivaracetam tablets in India | Pharmasources.com

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Manulife Hong Kong today announced a new partnership with New Frontier Group, one of the leading healthcare service providers in Greater China, to introduce cashless services for eligible customers through New Frontier Group's subsidiary, Prosper Health.

You may like
More>>

Mifepristone (INDIA DMF)

Mifepristone (INDIA DMF)
100% Pure Freeze Dried Black Berry Anthocyanin Juice Indian Instant Fruit Blackberry Powder

100% Pure Freeze Dried Black Berry Anthocyanin Juice Indian Instant Fruit Blackberry Powder
Indian Trum etflower Seed Extract

Indian Trum etflower Seed Extract

Brivaracetam

Brivaracetam
brivaracetam

brivaracetam
Brivaracetam, API

Brivaracetam, API
Brivaracetam

Brivaracetam
Brivaracetam Impurity 2

Brivaracetam Impurity 2
 Brivaracetam

 Brivaracetam
Top Quality Indian Bread P.E.

Top Quality Indian Bread P.E.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service